灯盏花素联合川芎嗪对NSCLC的抑制作用及其机制研究

摘要/Abstract

摘要： 目的探讨灯盏花素联合川芎嗪对NSCLC的抑制作用及其机制。方法将非小细胞肺癌A549细胞分为对照组,灯盏花素组（60 μmol/L）、川芎嗪组（40 μmol/L）、灯盏花素联合川芎嗪组（灯盏花素：60 μmol/L;川芎嗪：40 μmol/L）,使用MTT法检测细胞存活率、流式细胞术检测细胞凋亡、Transwell试验检测细胞迁移能力、Western Blot实验检测相关通路变化。结果对照组、灯盏花素组、川芎嗪组、灯盏花素联合川芎嗪组A549细胞24 h后的细胞存活率依次呈降低趋势（P<0.05）;与对照组相比,给药后的A549细胞出现明显的凋亡情况,且灯盏花素和川芎嗪联合用药组肺癌细胞凋亡最明显;Transwell实验结果显示,与对照组相比,给药后穿膜细胞数量显著减少,且灯盏花素联合川芎嗪抑制细胞穿膜效果最显著;Western Blot实验显示,给药后p-JAK2和p-STAT3的表达降低,且灯盏花素联合川芎嗪组中两种蛋白表达量最低。结论灯盏花素联合川芎嗪可抑制非小细胞肺癌细胞系A549的增殖、迁移和侵袭,其机制可能与JAK-STAT通路被抑制有关。

关键词: 灯盏花素, 川芎嗪, 非小细胞肺癌

Abstract: Objective To investigate the mechanism of inhibition of NSCLC by combination of Breviscapine and Tetramethylpyrazine. Methods Non-small cell lung cancer A549 cells were divided into control group, Breviscapine group, Tetramethylpyrazine group,Breviscapine and Tetramethylpyrazine group. Detect cell survival rate by MTT, apoptosis by flow cytometry, cell migration ability by Transwell test. Related pathway changes were detected by Western Blot. Results The cell survival rate of A549 cells in the control group, Breviscapine group, Tetramethylpyrazine group, and Breviscapine and Tetramethylpyrazine group decreased after 24h (P<0.05). Compared with control group, A549 cells showed significant apoptosis and cells in Breviscapine and Tetramethylpyrazine group showed the most evident changes; Transwell showed that the number of trans-membranous cells decreased significantly compared with the control group and membrane penetration was most evidently inhibited in combination group. Western blot showed that the expression of p-JAK2 and p-STAT3 decreased after drug administration, and the two proteins were lowest in the Breviscapine and Tetramethylpyrazine group. Conclusion Breviscapine combined with Tetramethylpyrazine inhibited the proliferation, migration and invasion of the non-small cell lung cancer cell line A549, and the mechanism may be related to the inhibition of the JAK-STAT pathway.

Key words: Breviscapine, Tetramethylpyrazine, non-small cell lung cancer

中图分类号:

R285

史莉萍, 刘地林, 吕根梅. 灯盏花素联合川芎嗪对NSCLC的抑制作用及其机制研究[J]. 中华养生保健, 2023, 41(16): 18-21.

SHI Li-ping, LIU Di-lin, LYU Gen-mei. Inhibition of NSCLC by Combination of Breviscapine and Tetramethylpyrazine and its Mechanism[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(16): 18-21.

参考文献

[1] LEMJABBAR-ALAOUI H, HASSAN O U, YANG Y W, et al.Lung cancer: Biology and treatment options[J]. Biochim Biophys Acta,2015, 1856(2):189-210.
[2] HIRSCH F R, SCAGLIOTTI G V, MULSHINE J L, et al.Lung cancer: current therapies and new targeted treatments[J]. Lancet,2017, 389(10066):299-311.
[3] XIANG Y, GUO Z, ZHU P, et al.Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science[J]. Cancer Med,2019,8(5):1958-1975.
[4] WANG Y, ZHANG Q, CHEN Y, et al.Antitumor effects of immunity-enhancing traditional Chinese medicine[J]. Biomed Pharmacother,2020, 121:109570.
[5] WANG K, CHEN Q, SHAO Y, et al.Anticancer activities of TCM and their active components against tumor metastasis[J]. Biomed Pharmacother, 2021,133:111044.
[6] GAO J, CHEN G, HE H, et al.Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review[J]. Front Pharmacol,2017,23(8):289.
[7] LI Y, LI S, LI D.Breviscapine Alleviates Cognitive Impairments Induced by Transient Cerebral Ischemia/Reperfusion through Its Anti-Inflammatory and Anti-Oxidant Properties in a Rat Model[J]. ACS Chem Neurosci,2020, 11(24):4489-4498.
[8] 唐钧,曹红梅,余婷婷,等.灯盏花素通过Nrf2/HO-1抑制缺血性脑卒中脑内氧化损伤的作用研究[J].老年医学与保健,2022,28(4):756-760.
[9] 石露露,韩卫南,王强,等.灯盏花素调控Nrf2/Gpx4通路对MIRI模型心肌凋亡的影响及作用机制研究[J].天津中医药,2022,39(9):1182-1186.
[10] ZHANG H, TANG W, WANG S, et al.Tetramethylpyrazine Inhibits Platelet Adhesion and Inflammatory Response in Vascular Endothelial Cells by Inhibiting P38 MAPK and NF-κB Signaling Pathways[J]. Inflammation,2020,43(1):286-297.
[11] 张昌林,倪小佳,李春花,等.川芎嗪的结构修饰及生物活性研究进展[J].中药新药与临床药理,2017,28(4):549-556.
[12] 纪新博,符碧薇,顾申红,等.基于Notch通路研究川芎嗪注射液对老年心肌梗死大鼠心肌细胞增殖、凋亡的影响[J].中国老年学杂志,2022,42(15):3813-3817.
[13] 刘桐,陆婷婷,高雅婷,等.活血化瘀类中药相关活性成分发挥肿瘤放疗增敏作用的药效学基础[J].中药药理与临床,2022,38(2): 236-241.
[14] 季进锋,许春明,张慧,等.中药补康灵方联合安罗替尼靶向治疗晚期非小细胞肺癌临床疗效观察[J].中医药学报,2021,49(8):81-86.
[15] WEI W, WANG L, XU L, et al.Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4[J]. J Thorac Dis,2021,13(4):2475-2485.
[16] Zeng J, Cai S.Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression[J]. J Biosci,2017, 42(1):121-129.
[17] 孙亚棋,聂旭阳,高敬林,等.P-糖蛋白介导的川芎嗪逆转肿瘤细胞多药耐药机制研究进展[J].中国新药杂志,2022,31(16):1580-1583.
[18] 李华. 川芎嗪对结肠癌细胞的抑瘤效应及改变线粒体活性氧代谢介导凋亡通路的机制研究[D].南京:南京中医药大学,2021.
[19] 李万玉,徐晓玉,杨辰锴.川芎嗪抗癌作用及其机制的分析[J].中国当代医药,2011,18(22):24-25.
[20] JIA Y, WANG Z, ZANG A, et al.Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling[J]. Int J Oncol,2016,48(5):2079-2086.
[21] 周新欢,杨弋弋,任红娟,等.基于JAK-STAT信号通路探讨槲皮素对宫颈癌细胞增殖、凋亡和转移的影响[J].新中医,2022,54(21):144-148.
[22] 于镓锐,杨森,钟洪波,等.藤黄酸通过抑制JAK-STAT通路对食管癌细胞KYSE450增殖和凋亡的影响[J].实用肿瘤杂志,2021,36(3):228-233.